EXCEPTIONAL CASE

Successful treatment of refractory hypertension with bilateral nephrectomy in a patient with chronic kidney disease stage 3

Anna M. Zemke, Roger A. Rodby, Martin Hertl, Ali Waleed and George L. Bakris

1Department of Medicine, Rush University, Chicago, IL, USA, 2Department of Surgery, Rush University, Chicago, IL, USA and 3Department of Medicine, University of Chicago, Chicago, IL, USA

Correspondence to: Anna M. Zemke; E-mail: anna_m_zemke@rush.edu

ABSTRACT

We present a case of life-threatening refractory hypertension (rHTN) in a patient with stage 3b chronic kidney disease that was unresponsive to open surgical renal denervation (RDN) but responded to bilateral nephrectomy (BLN). Both RDN and BLN reduce the increased sympathetic activation in rHTN. However, RDN has yet to show reductions in blood pressure adequate for the average patient with rHTN, and BLN has thus far been reserved for patients with preexisting end-stage kidney disease (ESKD). Our case suggests that there are patients with rHTN that warrant consideration of BLN prior to developing ESKD.

Keywords: nephrectomy, refractory hypertension, renal denervation, sympathetic nervous system

INTRODUCTION

Uncontrolled refractory hypertension (rHTN) causes long-term vascular damage and increased mortality [1]. Advancements in antihypertensive medications have led to a significant decline in rates of rHTN over the past few decades. However, if these fail, there remain limited nonpharmacologic treatment options. Targeting the sympathetic input to the kidneys has gained attention with ongoing studies in renal denervation (RDN).

Studies prior to the emergence of antihypertensive medications demonstrated that surgical splanchnicectomy, disrupting sympathetic nerves in the thoracic and lumbar regions, was effective at substantially decreasing blood pressure (BP), but brought disabling side effects secondary to its untargeted approach [2–4]. With subsequent enhancements in the efficacy and tolerability of antihypertensive medications, including the development of minoxidil in the 1970s, this nonspecific approach to rHTN fell out of favor [5].

More specific approaches of removing sympathetic output from the kidney focus on various means of RDN, attempting to achieve the same effect of splanchnic sympathectomy without the systemic side effects. Recent randomized sham-controlled RDN trials include SPYRAL HTN-ON MED, SYRAL HTN-OFF MED and RADIANCE-HTN SOLO [6]. While successful in lowering BP, they demonstrated on average only a 4–8 mmHg placebo subtracted reduction in systolic BP (SBP) [6]. These BP reductions would not be adequate for the average patient with rHTN. It has been proposed that the marginal success of these RDN trials is because of insufficient renal sympathetic ablation (on average as low as 40%) as well as sympathetic nerve regrowth [7, 8].

Ultimately, the best way to completely disrupt sympathetic output from the kidneys is to remove them. Several studies have
shown that bilateral nephrectomy (BLN) is the most effective method at lowering BP in rHTN [9]. BLN thus became popular for rHTN in patients with end-stage kidney disease (ESKD) in the 1970s to lower BP, and it also improved survival and reduced neurological, ocular and cardiovascular complications [1]. Previous studies also show a consistent improvement in quality of life measures in these patients [1, 10]. Authors of several of these studies have thus argued for early nephrectomy in ESKD patients with rHTN [11].

We present a case of severe rHTN in a patient with stage 3b CKD, unresponsive to open surgical RDN (OS-RDN), who underwent BLN as a last resort to treat what we considered a life-threatening condition. This resulted in an abrupt and persistent decrease in BP.

**CASE REPORT**

A 43-year-old white woman with stage 3b CKD (estimated glomerular filtration rate (eGFR) 38 mL/min/1.73 m²) with a 16-year history of HTN presented with a resting SBP between 180 and 240 mmHg on maximal doses of eight different antihypertensive medications including minoxidil (Figure 1, Table 1). Her past medical history is notable for polycystic ovarian syndrome and type 2 diabetes. Her kidney function was initially normal, but started to decline 6 years after her initial HTN diagnosis (Figure 2). HTN workup occurred with regular follow-up at a comprehensive HTN center, which excluded all secondary causes including drug screenings, urine metanephrines, renal magnetic resonance imaging (MRI) and renin/aldosterone ratios. (Table 2). There were no issues with medication adherence and she was observed taking medications in clinic but consistently remained hypertensive, with the lowest measurement 172/90. Despite being trialed on several different home regimens, she continued to have frequent hospitalizations and ED visits for symptomatic HTN, averaging one every 3–4 weeks. The only regimen that controlled her BP to 130s systolic was the combination of intravenous calcium channel blockade and beta-blockers.

She initially underwent bilateral OS-RDN by severing all neural tissue entering the kidney. Briefly, this was done by retroperitoneal exploration of both kidneys with complete dissection of tissue around the renal artery, vein and ureter, similar to what would be done for living donor nephrectomy. Bilateral renal vein renin levels were measured before and after OS-RDN and were 9.1, 7.8 ng/mL/h and 0.7, 1.4 ng/mL/h, respectively. Despite an initial drop in BP to 140/70 mmHg on only two medications, within 4 weeks of OS-RDN, her BP rose to 240/120 despite reintroducing her pre-OS-RDN medications, and she was again symptomatic.
Successful treatment of refractory HTN with bilateral nephrectomy in a patient with CKD 3

Table 2. Workup of secondary causes of hypertension

| Potential causes of HTN                  | Patient workup                                                                 |
|-----------------------------------------|-------------------------------------------------------------------------------|
| Congenital adrenal hyperplasia          | 11-beta-hydroxylase levels normal (8)                                         |
| Cushing syndrome                        | Morning cortisol was not elevated (9, 8, 3)                                   |
| Elicit substance use                    | Dexamethasone suppression test normal (8)                                     |
| Fibromuscular dysplasia                 | MRI angiogram without evidence of stenosis, aneurysmal dilation or beading (1) |
| Inaccurate office readings              | The patient kept detailed logs of her home BP readings                        |
| Medication nonadherence                 | Patient with consistent follow-up with multiple providers, direct observed medication therapy in clinic, filled all medications regularly |
| Obstructive sleep apnea                 | Wears CPAP with good adherence per machine logs                               |
| Pheochromocytoma                        | Serum renin aldosterone ratio normal (9, 0)                                   |
| Primary hyperaldosteronism              | Systemic renin still low post-procedure                                       |
| Renal artery stenosis                   | Renal ultrasound with Dopplers negative for RAS (4, 0)                        |
| Renal disease                           | Serum creatinine level and GFR normal for several years after HTN dx          |
| Thyroid disorders                       | Negative/normal: ANA, C3, C4, hepatitis B and C and phospholipase A2 receptor antibody (8) |

(Numbers) indicate number of years prior to RDN that this workup was completed. CPAP, continuous positive airway pressure; RAS, reninangiotensin system; ANA, anti-nuclear antibody; TSH, thyroid-stimulating hormone.

FIGURE 2: Trend in serum creatinine and urine microalbumin creatinine ratio from time of diagnosis of HTN to RDN 16 years later.

At this point, BLN was proposed as the only remaining option. Understanding the need for renal replacement therapy (RRT) following BLN, the patient consented to proceed. BLN was done in retroperitoneal approach through the same incisions as the OS-RDN. Follow-up BPs have persistently been in the 130/80 mmHg range on only carvedilol 12.5 mg twice daily (Figure 1).

DISCUSSION

Pre-ESKD BLN for rHTN has not been previously reported, and there are only limited case reports of surgical RDN from one institution in 1935 [12]. Decreasing sympathetic nerve input to the kidneys for BP control is supported by the effectiveness of alpha b-adrenergic blockers in many patients, splanchic denervation observations as early as the 17th century, several BLN studies in ESKD or post-renal transplant, as well as catheter RDN in several animal studies [13].

Advancements in endovascular RDN are becoming more effective, but still only lower SBP by 4-8 mmHg placebo subtracted [7]. Our case failed to respond to OS-RDN despite complete dissection of all extramural autonomous nerves and surrounding connective tissue. This suggests that the effects of RDN of any form may be limited. Our patient’s BP initially appeared controlled following OS-RDN, but after 4 weeks, she re-presented to the hospital with uncontrolled HTN. One explanation for this, and one of the growing concerns about RDN, is renal nerve regeneration, which we were able to demonstrate by pathologic examination of the kidneys after nephrectomy (data not shown). Animal studies in sheep show both anatomical and functional regeneration of the renal nerves in less than a year following RDN [14]. While we do not have data for nerve regeneration in human RDN, previous human studies with transplanted kidneys showed evidence of renal nerve regeneration starting at 4 weeks posttransplant [15].

BLN for rHTN for patients on RRT was initiated in the 1970s. Almost 50 years later, despite enormous improvements in medications, there is still a role for this procedure. Requiring this in a patient pre-ESKD resulting in dialysis dependence was an extreme, but we felt life-saving, requirement to prevent stroke and other organ failure. She has been referred for transplantation. Advances in catheter ablation are encouraging, but long-term efficacy will need to be assessed. Currently, most RDN studies have not followed patients beyond a couple of months. This case raises concerns that long-term efficacy of RDN might face more challenges than solely improvement of technique.

CONFLICT OF INTEREST STATEMENT

G.L.B. has been a consultant with Merck, Bayer, Vascular Dynamics, KBP Biosciences, Ionis, Alnylam, Astra Zeneca, Quantum Genomics, Horizon and Novo Nordisk. He is on Research support–Steering committees of trials—Bayer, Vascular Dynamics, Quantum Genomics, Alnylam, Novo Nordisk—and is an editor at the American Journal of Nephrology.

All other authors have no conflict of interest or disclosures to report.
PATIENT CONSENT

The authors declare that they have obtained consent from the patient discussed in the report.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

REFERENCES

1. Cruz I, Callender CO, Cummings Y et al. Malignant hypertension revisited: the role of bilateral nephrectomy. J Natl Med Assoc 1980; 72: 453–457
2. Newcombe CP, Shucksmith HS, Suffern WS. Sympathectomy for hypertension; follow-up of 212 patients. Br Med J 1959; 1: 142–144
3. Grimson KS, Orgain ES, Anderson B et al. Results of treatment of patients with hypertension by total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy. Ann Surg 1949; 129: 850–871
4. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension: results in 1,266 cases. JAMA 1953; 152: 1501–1504
5. Pettinger WA, Mitchell HC. Minoxidil—an alternative to nephrectomy for refractory hypertension. N Engl J Med 1973; 289: 167–171
6. Stavropoulos K, Patoulas D, Imprialos K et al. Efficacy and safety of renal denervation for the management of arterial hypertension: a systematic review and meta-analysis of randomized, sham-controlled, catheter-based trials. J Clin Hypertens (Greenwich) 2020; 22: 572–584
7. Esler M. Illusions of truths in the simplicity HTN-3 trial: generic design strengths but neuroscience failings. J Am Soc Hypertens 2014; 8: 593–598
8. Mahfoud F, Lüscher TF. Renal denervation: simply trapped by complexity? Eur Heart J 2015; 36: 199–202
9. Alidabat M, Alabdallah K, Kofahi A et al. Bilateral nephrectomy, the forgotten measure in the treatment of refractory hypertension in patients with end-stage renal disease: a case report and literature review. Cureus 2020; 12: e9031
10. Zazgornik J, Biesenbach G, Janko O et al. Bilateral nephrectomy: the best, but often overlooked, treatment for refractory hypertension in hemodialysis patients. Am J Hypertens 1998; 11: 1364–1370
11. Lazarus JM, Hampers CL, Bennett AH et al. Urgent bilateral nephrectomy for severe hypertension. Ann Intern Med 1972; 76: 733–739
12. Page IH, Heuer GJ. The effect of renal denervation on patients suffering from nephritis. J Clin Invest 1935; 14: 443–458
13. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010; 298: R245–R253
14. Booth LC, Nishi EE, Yao ST et al. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension 2015; 65: 393–400
15. Gazdar AF, Dammin GJ. Neural degeneration and regeneration in human renal transplants. N Engl J Med 1970; 283: 222–224